Coya Therapeutics Inc (COYA) - News Archive

Houston-based Coya Therapeutics, Inc. a clinical-stage biotechnology company focusing on the enhancement of regulatory T cell (Treg) function, has announced promising results from a recent study evaluating low-dose inte...

Title : Coya Therapeutics Expands Investigational Pipeline and Appoints New CEO to Drive Biologics Development for Inflammatory Diseases:Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology firm focuse...

In the ever-evolving landscape of biotechnology, leadership transitions can often signal significant changes in a company s strategic direction. Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotech firm focu...

Coya Therapeutics Appoints Arun Swaminathan, Ph.D. as New CEO: A Strategic Move for Treg-Focused Biologics Development Coya Therapeutics, Inc. a clinical-stage biotechnology company focused on developing biologics to en...

Leadership Transition at Coya Therapeutics: An Update on Arun Swaminathan’s Appointment as CEO On November 1, 2024, Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology enterprise known for its pioneer...

Coya Therapeutics, Inc. (NASDAQ: COYA) has been gaining recognition and momentum in the biotechnology world. The company, which focuses on developing biologics to enhance regulatory T cell (Treg) function, is making str...

Coya Therapeutics Unveils Promising Subcutaneous Treatment for Parkinson’s Disease in Preclinical Mouse Model Regulatory T Cell Enhancement Shows Anti-Inflammatory Effects in the Brain Houston Coya Therapeutics, Inc. (N...

Houston, TX October 10, 2024 Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company focused on developing biologics to enhance regulatory T cell (Treg) function, has several exciting announcement...

: Coya Therapeutics, Inc., a clinical-stage biotechnology firm, has announced a significant step forward in its therapeutic pipeline with the recent filing of new U.S. patents covering the combination of COYA 301 (recom...

Coya Therapeutics, a clinical-stage biotechnology company focused on developing biologics to enhance regulatory T cell (Treg) function, has recently announced its inclusion in the MSCI USA Micro Cap Index. This signific...

Coya Therapeutics Completes Phase 2 Study of Low Dose Interleukin-2 in Alzheimer s Disease PatientsHouston-based biotechnology company, Coya Therapeutics, Inc. (NASDAQ: COYA), has recently announced the successful compl...

Coya Therapeutics, a clinical-stage biotechnology company, recently announced a strategic investment of $5 million from the Alzheimer s Drug Discovery Foundation (ADDF). The ADDF purchased 603,136 shares of Coya s commo...

Coya Therapeutics, a clinical-stage biotechnology company focused on enhancing regulatory T cell function, recently presented updated ALS biomarker data at the 2nd Annual Johnson Center Symposium. Additionally, the comp...

Coya Therapeutics, a reputable clinical-stage biotechnology company focused on developing biologics to enhance regulatory T cell (Treg) function, has recently made significant progress in the field of Amyotrophic Latera...

Coya Therapeutics, a renowned clinical-stage biotechnology company, recently made an exciting announcement regarding the expansion of their therapeutic program COYA 302 into Alzheimer s Disease. The news comes in the fo...

Coya Therapeutics Acquires Patent License to Advance Next Generation Immune Modulatory Biologics for Inflammatory Diseases, Boosting Regulatory T CellsHOUSTON - Coya Therapeutics, a leading clinical-stage biotechnology...

In the bustling realm of biotechnology, companies are continually striving to create groundbreaking advancements that pivot the needle in global health. One such enterprise that has been carving a distinctive niche for...

In a groundbreaking move, Coya Therapeutics, Inc. and Dr. Reddy s Laboratories Ltd. have joined forces to develop and commercialize COYA 302, an investigational combination therapy for the treatment of Amyotrophic Later...